NangioTx

NangioTx is a New Jersey-based pharmaceutical company specializing in the development of innovative peptide-drug formulations. We focus on blood-vessel regeneration, utilizing our patent-pending V-10 peptide to restore blood flow and promote tissue regeneration – a critical approach for treating peripheral artery disease and potentially saving limbs.

Our core expertise lies in revascularization therapies, targeting the underlying causes of vascular impairment. We are dedicated to advancing the field of cardiovascular medicine through targeted drug delivery systems.

NangioTx’s approach centers on leveraging the regenerative potential of peptides to address unmet medical needs. We are committed to rigorous research and development, with a growing presence in Boston, Massachusetts, alongside our headquarters in New Jersey. We aim to transform patient outcomes through groundbreaking therapies.